The Queensland Institute of Medical Research, Bacterial Pathogenesis Laboratory, Brisbane, Australia. David.McMillan@qimr.edu.au
ID Biomedical, under license from the University of Tennessee, is developing StreptAvax, a potential subunit vaccine against group A streptococcal infection. By January 2005, analysis of data from phase II clinical trials conducted in adults was completed. Pediatric trials are not expected to begin before 2007.